Translational biomarkers: Essential tools in development of antibody-based therapeutics

Abstract

A science-based approach for translation of exposure-response data is vital for effective advancement of antibody-based therapeutics and application of relevant biomarkers can streamline this process significantly. Selecting and evaluating relevant biomarkers early on not only lessens the time and cost associated with clinical evaluation, but also fosters implementation of rational decision-making processes throughout various antibody development phases.